Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Combinations in Anaplastic and Poorly Differentiated Thyroid Carcinomas
NCT03181100Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2017
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in anaplastic thyroid carcinoma (ATC) and poorly differentiated thyroid carcinoma (PDTC) (4 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Survival at 5 years. Started Jul 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
anaplastic thyroid carcinoma (ATC)poorly differentiated thyroid carcinoma (PDTC)
Beyond the preview
Go deeper on NCT03181100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03181100.